Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 45Neoplasms 5Colorectal Neoplasms 5Neoplasm Metastasis 3Adenocarcinoma 3Resectable Pancreatic Cancer 2Rectal Neoplasms 2Pancreatic Cancer Metastatic 2Carcinoma, Hepatocellular 2Biliary Tract Neoplasms 2Stomach Neoplasms 1Pancreatic Ductal Adenocarcinoma (PDAC) 1Pancreatic Cancer Non-resectable 1Pancreatic Adenocarcinoma 1Neoplasms, Basal Cell 1Locally Advanced Pancreatic Adenocarcinoma 1Localized Pancreatic Adenocarcinoma 1Gastrointestinal Neoplasms 1Gastroesophageal Adenocarcinoma 1Gastro-enteropancreatic neuroendocrine tumor 1Diabetes Mellitus, Insulin-Dependent, 12 1Colorectal Cancer Metastatic 1Colonic Neoplasms 1Cholangiocarcinoma 1Carcinoma, Pancreatic Ductal 1Carcinoma, Islet Cell 1Carcinoma 1Borderline Resectable Pancreatic Cancer 1

Interventions

Gemcitabine 13Albumin-Bound Paclitaxel 8Taxes 6130-nm albumin-bound paclitaxel 6Fluorouracil 5Oxaliplatin 4dehydroftorafur 3Radiotherapy, Intensity-Modulated 3Radiotherapy 3Leucovorin 3Irinotecan 3Losartan 2Cisplatin 2tocilizumab 1selicrelumab 1niraparib 1irinotecan sucrosofate 1indusatumab 1folfirinox 1durvalumab 1cobimetinib 1atezolizumab 1X-Rays 1Tiragolumab 1Surgical Procedures, Operative 1Standard of Care 1Specimen Handling 1S 1 (combination) 1Resistance Training 1Radiotherapy, Image-Guided 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pancreatic Adenocarcinoma × folfirinox × Gastrointestinal × Clear all
NCT05181605 2022-08-09

Survival Analysis After Neoadjuvant Therapy in Patients With Resectable Pancreatic Cancer and Risk Factors

Instituto de investigación e innovación biomédica de Cádiz

Phase 2/3 Unknown
116 enrolled
Gastrointestinal

Pancreatic Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡